Stereotaxis Signs Distribution Agreement for Niobe(R) Technology in Japan

Stereotaxis Signs Distribution Agreement for Niobe(R) Technology in Japan

ST. LOUIS, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
announced today that it has entered into a definitive agreement with Medix
Japan, Inc. and Hokushin Medical Co. Ltd. to distribute its Niobe® Magnetic
Navigation System for cardiac ablations in Japan. The agreement ensures sales
and marketing coverage for Stereotaxis in an electrophysiology (EP) market
performing approximately 47,000 procedures each year and expected to grow at
an annual rate of 10% through 2018. Japan also represents one of the largest
medical device markets globally, second to the U.S.

"We are very pleased to have the assistance of Medix Japan and Hokushin
Medical in bringing our expertise with automated, remote navigation solutions
to the Japanese EP community," said William C. Mills, Stereotaxis Chief
Executive Officer. "With an aging population and increasing rate of
arrhythmias and other cardiac conditions, we can offer EP physicians in Japan
greater possibilities in the treatment of their complex cases and make a
difference in patient quality of life. We are confident that these two
companies, both experts in product promotion with deep understanding of the
Japanese medical device industry and strong entrepreneurial spirit, will
enthusiastically support our vision in a vital new market." 

Founded in 1987, Hokushin Medical Co. Ltd. is based in Kobe, Japan. The
Company's core business is in marketing, distributing and servicing
cardiovascular products. Hokushin Medical is one of the largest distributors
of EP products in Japan, with extensive hospital relationships. Since 1975,
Medix Japan, Inc., based in Fukuoka, Japan, has been importing and selling
medical devices and pharmaceuticals in Japan. The Company has significant
regulatory and quality management expertise required to handle highly
regulated medical products. Medix Japan's parent company, Kamachi Group, is a
diversified conglomerate with approximately $100 billion in annual sales,
which also owns and operates 17 hospitals.

Under the agreement, Hokushin Medical will market, sell and distribute the
Niobe system and disposable devices to Japanese customers, as well as provide
customer training and clinical support. Medix Japan will lead the completion
of the post marketing surveillance project as required by Japan's
Pharmaceuticals and Medical Devices Agency. Furthermore, Medix Japan will be
charged with securing market authorization of Stereotaxis' Vdrive™ Robotic
Navigation System and Odyssey® Information Management Solution in the coming
months, in order to offer the advantages of the full Epoch™ Solution to the
Japanese market.

"Hospitals and physicians in Japan are eager for new technologies that deliver
safer, simpler and less invasive patient therapies," said Mitsunori Furukawa,
Chief Executive Officer of Hokushin Medical. "We are passionate about the
Stereotaxis product suite and excited to collaborate with Medix Japan in
representing the Stereotaxis brand to elevate the level of arrhythmia care in

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. Over 100 issued
patents support the Stereotaxis platform, which helps physicians around the
world provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced collaboration of
life-saving information. Stereotaxis' core Epoch™ Solution includes the Niobe®
ES Remote Magnetic Navigation system, the Odyssey® portfolio of lab
optimization, networking and patient information management systems and the
Vdrive™ Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance
in the U.S., European Union, Canada, China and elsewhere. The V-Sono™ ICE
catheter manipulator has received U.S. clearance, and the V-Loop™ circular
catheter manipulator will soon be submitted for review by the U.S. Food and
Drug Administration. For more information, please visit

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, the Company's ability to
raise additional capital on a timely basis and on terms that are acceptable,
its ability to continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend, repay or
refinance indebtedness on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global economic
conditions on the ability and willingness of customers to purchase its systems
and the timing of such purchases, the outcome of various shareholder
litigation filed against Stereotaxis, competitive factors, changes resulting
from the recently enacted healthcare reform in the U.S., including changes in
government reimbursement procedures, dependence upon third-party vendors,
timing of regulatory approvals, and other risks discussed in the Company's
periodic and other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no obligation
to update these statements for revisions or changes after the date of this
release. There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any particular period
or at all because some of these purchase orders and other commitments are
subject to contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified, delayed or
canceled, either by their express terms, as a result of negotiations, or by
overall project changes or delays.

CONTACT: Company Contact:
         Marty Stammer
         Chief Financial Officer
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.

Stereotaxis logo
Press spacebar to pause and continue. Press esc to stop.